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ABSTRACT Cdc6 has a critical regulatory role in the
initiation of DNA replication in yeasts, but its function in
mammalian cells has not been characterized. We show here
that Cdc6 is expressed selectively in proliferating but not
quiescent mammalian cells, both in culture and within tissues
of intact animals. During the transition from a growth-
arrested to a proliferative state, transcription of mammalian
Cdc6 is regulated by E2F proteins, as revealed by a functional
analysis of the human Cdc6 promoter and by the ability of
exogenously expressed E2F proteins to stimulate the endog-
enous Cdc6 gene. Immunodepletion of Cdc6 by microinjection
of anti-Cdc6 antibody blocks initiation of DNA replication in
a human tumor cell line. We conclude that expression of
human Cdc6 is regulated in response to mitogenic signals
though transcriptional control mechanisms involving E2F
proteins, and that Cdc6 is required for initiation of DNA
replication in mammalian cells.
In yeasts, Cdc6 (Saccharomyces cerevisiae) and Cdc18 (Schizo-
saccharomyces pombe) associate with the origin recognition
complex (ORC) proteins to render cells competent for DNA
replication (1–10). The association of Cdc6 with ORC alters
the nucleotide contacts made by origin binding proteins (11)
and promotes recruitment of MCM proteins and other factors
required to form prereplication complexes (12, 13). Initiation
of DNA replication also requires the activity of S-phase
promoting protein kinases that include cyclin:cdk and
Cdc7:Dbf4 complexes (1).
Cdc6-related proteins recently have been characterized
from both human(14) and Xenopus cells (14, 15), but only
limited information is available with respect to the expression
and function of Cdc6 in higher eukaryotes. Xenopus Cdc6 was
shown to bind ORC and to promote assembly of MCM
proteins onto chromatin. In addition, immunodepletion of
Cdc6 blocked initiation in a cell free replication assay that uses
Xenopus oocyte extract and sperm chromatin (15). We have
reported that human Cdc6 mRNA and protein were not
detected in serum-deprived human diploid fibroblasts, and
that expression of human Cdc6 was induced, prior to the G1yS
transition, when these cells were stimulated by serum to enter
the cell cycle (14).
In this study, we addressed several questions. Is the associ-
ation between Cdc6 expression and proliferative cell growth
evident in a different cell culture model of growth arrest
(contact inhibition versus serum starvation), and in tissues of
intact animals? What regulatory mechanisms act upstream to
control expression of Cdc6? Is Cdc6 required for initiation of
DNA replication in mammalian cells? The results presented
here demonstrate that mammalian Cdc6 is subject to strict
regulation in response to mitogenic growth signals through
mechanisms that involve E2F transcription factors. The timing
of Cdc6 expression in the transition from G0 to G1 is consistent
with its postulated role in DNA replication, and immunodeple-
tion of Cdc6 blocks entry of human cells into S phase. These
results support the hypothesis that human Cdc6, like its yeast
counterparts, participates in assembly of prereplication com-
plexes. In addition, these data indicate that Cdc6, a protein
likely to function directly at origins of DNA replication, is a
downstream target of molecular signaling pathways that con-
trol the G1yS transition.
MATERIALS AND METHODS
Analysis of Cdc6 Expression. Immunoblots were performed
as described (16) using purified rabbit polyclonal antibodies
generated in our laboratory against human Cdc6, or other
antibodies obtained from commercial sources [cyclin A (Santa
Cruz Biotechnology), PCNA (Calbiochem), cdc2 (Transduc-
tion Laboratory, Lexington, KY), and Sp1 (Santa Cruz Bio-
technology)]. Northern hybridizations were performed by
standard procedures using a cloned human Cdc6 cDNA as the
probe (14). Indirect immunofluorescence of cultured human
cells was performed as described (17) using rabbit anti-human
Cdc6 as the primary antibody and goat anti-rabbit IgG con-
jugated to fluorescein isothiocyanate as the secondary anti-
body. In situ hybridizations were performed as described (18,
19) on paraffin sections of duodenum from adult mice. Spe-
cies-specific, radiolabeled probes were generated by in vitro
transcription in the presence of 33P-UTP from a DNA tem-
plate containing a murine Cdc6 gene fragment corresponding
to nucleotides 983-1184 of human Cdc6 cDNA (14).
Analysis of Human Cdc6 Promoter Activity. We previously
cloned the human Cdc6 gene from a chromosome 17-specific
cosmid library (14) and determined the transcriptional start
site by primer extension analysis of HeLa cell mRNA. This
position corresponded to the 59 terminus of the longest Cdc6
cDNA clones that could be isolated from a HeLa cell library
or by 59 rapid amplification of cDNA ends using mRNA from
human 293 cells as the template. A KpnI-SacI DNA fragment
encompassing the human Cdc6 promoter region (21,700 to
17) was ligated to the firefly luciferase gene in pGL3 (Pro-
mega). Electrophoretic mobility shift assays were performed
as described (16) to assess binding of E2F proteins to a
double-stranded deoxyoligonucleotide representing putative
E2F binding motifs from wild-type or mutated Cdc6 promoter
sequences.
Using a PCR-mediated mutagenesis method (20), nucleo-
tide substitutions were introduced into both of the two putative
E2F binding sites at nucleotide positions 243 to 236 and 28
to 21 relative to the transcriptional start site. Specifically, the
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sequence motifs TTTGGCGG and TTTGGCGC were con-
verted to AATTCCGG and AAAGCTTG, respectively. Plas-
mids bearing wild-type or mutated human Cdc6 promoter
sequences were transfected into NIH 3T3 cells by using
Lipofectamine (GIBCOyBRL). The efficiency of transfection
was internally controlled by cotransfection of a pCMV-lacZ
expression plasmid. After transfection, subconfluent cells were
arrested from proliferative growth by serum starvation (0.1%
fetal bovine serum in DMEM) for 36 hr, and harvested at
various intervals following readdition of serum (10% fetal
bovine serum in DMEM). Whole cell lysates were prepared
and assayed for luciferase and b-galactosidase activity.
Recombinant Adenoviral Vectors. Complementary DNA
sequences encoding E2F1, E2F2, E2F3, or DP1 under the
control of a cytomegalovirus promoter were packaged into
infectious virions following homologous recombination into an
E1A-deleted Ad5 genome in 293 cells. A virus (Ad-Con)
lacking an insert in the cytomegalovirus expression cassette
was employed as a negative control. Recombinant virions were
purified by cesium chloride gradient density centrifugation and
titered by an immunofluorescence assay detecting expression
of the viral 72-kDa DNA binding protein (21).
Immunodepletion of Cdc6 in Human Cells. Rabbit poly-
clonal antibodies were raised against a fragment of human
Cdc6 (amino acids 51–172), and purified by ammonium sulfate
precipitation, followed by affinity chromotography over a
column prepared by linking the immunogen to Sepharose
beads (Affi10 column, Bio-Rad). The specificity of the anti-
Cdc6 antibody preparation was established by immunoblot,
immunofluorescence and immunoprecipitation assays. Puri-
fied anti-Cdc6 antibody produced a nuclear immunofluores-
cence pattern in cycling human HeLa cells that was unaffected
by preabsorption against immobilized glutathione S-
transferase. In contrast, preabsorption against an immobilized
human Cdc6-glutathione S-transferase fusion protein elimi-
nated the ability of purified antiserum to detect a nuclear
fluoresence signal in cycling human cells. In immunoblot
assays of nuclear protein extracts of HeLa cells transfected to
express either full length Cdc6 or a truncated Cdc6 variant
(amino acids 51–172) tagged with an influenza hemagglutinin
antigen epitope, both anti-hemagglutinin antigen and anti-
Cdc6 antibodies detected the same protein bands of the
predicted molecular sizes. Affinity-purified anti-Cdc6 anti-
body was concentrated to 1.5 mgyml in 0.53 PBS, and micro-
injected into metaphase cells identified by phase contrast
microscopy from among a population of subconfluent HeLa
cells growing asynchronously on a photo-etched coverslip
(Bellco Glass) in growth medium (DMEM supplemented with
10% fetal bovine serum). Cells were incubated subsequently in
growth medium containing 10 mM 5-bromodeoxyuridine (Br-
dUrd) for 15–18 hr, and the percentage of cells undergoing
DNA replication was determined after immunostaining by
using a mouse anti-BrdUrd mAb (Boehringer Mannheim).
Injected cells were identified by immunofluorescence using
goat anti-rabbit IgG conjugated to fluorescein isothiocyanate.
RESULTS
Expression of Cdc6 in Mammalian Cells and Tissues. We
demonstrated previously that expression of human Cdc6
mRNA and protein was suppressed by serum starvation of
cultured human diploid fibroblasts, and stimulated by the
readdition of serum (14). To determine whether intracellular
concentrations of Cdc6 are regulated in a similar manner by
other stimuli that control cell proliferation, we examined the
expression of Cdc6 in human T24 cells subjected to growth
arrest by contact inhibition in the presence of serum by
immunoblot and immunofluorescence techniques. During the
transition from G0 into the cell cycle, Cdc6 protein was first
detected about 4 hr prior to the initiation of S phase (Fig. 1).
The time course of Cdc6 induction was contemporaneous with
that of PCNA, but preceded that of cyclin A and cdc2. In the
immunofluorescence analysis, Cdc6 was localized predomi-
nately to the nuclei of asynchronously cycling T24 cells, but
could not be detected in contact-inhibited cells (Fig. 2).
The pattern of Cdc6 expression in cells of intact mammalian
tissues was assessed by in situ hybridization studies of mouse
tissues. Within normal intestinal epithelium, DNA replication
is limited to the crypts of Lieberku¨hn, while differentiated
epithelial cells that line the villi extending into the intestinal
lumen are quiescent. Expression of Cdc6 mRNA is evident
only within the proliferating cell population of this tissue (Fig.
3), a finding consistent with its postulated function in the
initiation of DNA synthesis.
Regulation of Cdc6 Transcription by E2F Proteins in Mam-
malian Cells. The prominent role of E2F transcription factors
in preparing cells for DNA replication (22), and the presence
of putative E2F binding sites within the proximal promoter
region of the human Cdc6 gene (14), suggested that Cdc6 gene
transcription could be regulated by E2F proteins.
We employed recombinant adenoviruses to determine
whether forced expression of E2F proteins could stimulate
transcription of the Cdc6 gene in growth arrested human cells.
Under conditions of serum deprivation, human foreskin fibro-
blasts expressed only low levels of Cdc6 mRNA, but forced
expression of either E2F1, E2F2, or E2F3, together with their
heterodimeric partner DP1, stimulated the accumulation of
Cdc6 mRNA in these quiescent human cells (Fig. 4A). This
induction of human Cdc6 expression was specific to adenovi-
ruses expressing E2F:DP1 proteins, and was not observed in
cells infected with comparable titers of a control virus.
FIG. 1. Induction of Cdc6 in human cells during release from
contact inhibition. (A) Immunoblot analysis of Cdc6 expression in
relation to other proteins at specific time points during entry into the
cell cycle. Human T24 cells were plated at high density (4 3 106
cellsy150 mm) in McCoy 5A media supplemented with 10% fetal
bovine serum and grown for 4 days. To release cells from contact
inhibition, they were trypsinized and replated at lower density (1 3 106
cellsy150 mm) in the same media. (B) Flow cytometric analysis of
DNA content in T24 cells samples at specific time points after release
from contact inhibition. The results show that contact-inhibited cells
are arrested with unreplicated DNA (2N), and that cells enter S phase
between 20 and 24 hr after release.
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To determine whether direct binding of E2F proteins to the
human Cdc6 promoter is pertinent to the control of Cdc6
transcription, a genomic fragment including the human Cdc6
promoter (nucleotides 21,700 to 17 relative to the transcrip-
tional start site) was linked to a luciferase reporter gene and
introduced by transfection into murine 3T3 cells. Under con-
ditions of growth arrest induced by serum deprivation, this
promoter was inactive, corresponding to low or undetectable
levels of endogenous Cdc6 mRNA (Fig. 4B). Addition of
serum, allowing 3T3 cells to reenter the cell cycle, increased
FIG. 2. Immunofluorescence staining of Cdc6 in proliferating human cells. Cdc6 is localized to the nucleus of asynchronously proliferating T24
cells (A) but is not detected in contact-inhibited cells (C). Propidium iodide staining (Right) identifies all the nuclei present within the same fields
(B and D).
FIG. 3. Selective expression of Cdc6 in proliferating cell populations within intact mammalian tissues. In situ hybridization of sections of
duodenum from an adult mouse by using antisense (A and B) or sense (C and D) probes, transcribed in vitro from Cdc6 cDNA. The boxed areas
in A and C are shown at higher magnification in B and D. (Bar 5 100 mm.)
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expression of the endogenous Cdc6 gene, and concomitantly
activated the exogenous reporter gene controlled by the hu-
man Cdc6 promoter.
Nucleotide substitutions within two E2F binding motifs
within the Cdc6 promoter (14) disrupted recognition of these
sites by E2F proteins, as assessed by electrophoretic mobility
shift assays (not shown) by using probes that represented
native or mutated Cdc6 promoter sequences. As assessed by
transient transfection assays in 3T3 cells, the human Cdc6
promoter bearing mutations in both E2F sites was actively
transcribed under serum starved conditions in which the
endogenous murine Cdc6 gene and the wild-type human Cdc6
promoter were transcriptionally inactive (Fig. 4B). These data
reveal a role for E2F in the control of Cdc6 transcription and
suggest that the Cdc6 gene is repressed in quiescent cells by an
E2F complex, in a manner similar to certain other downstream
targets of the E2F pathway, including E2F1 (23), B-Myb (24),
and Orc1 (25). The observation that overexpression of E2F
proteins led to activation of the endogenous Cdc6 gene could
represent displacement or inactivation of an E2F repressor
complex.
Immunodepletion of Cdc6 in Human Cells. To determine
whether human Cdc6 is required for initiation of DNA repli-
cation, an affinity-purified, polyclonal anti-Cdc6 antibody was
microinjected into HeLa cells. On the premise that immu-
nodepletion would be most effective if Cdc6 were neutralized
prior to formation of prereplication complexes, control or
anti-Cdc6 antibodies were introduced into metaphase cells,
and the ability of daughter cells to initiate DNA replication in
the next cell cycle was assessed by the incorporation of BrdUrd.
Cells injected at metaphase with either antibody were able to
complete mitosis and cytokinesis, and microinjected antibod-
ies could be detected in both daughter cells for at least 18 hr.
The majority of cells receiving the anti-Cdc6 antibody failed
to initiate DNA replication (Fig. 5 A–C). Only a small pro-
portion (11%) of cells receiving anti-Cdc6 antibody remained
competent to initiate DNA replication, and these cells exhib-
ited less intense immunofluorescent staining of the microin-
jected rabbit IgG, suggesting that the quantity of anti-Cdc6
antibody in these cells may have been insufficient to titrate out
endogenous Cdc6. In contrast, cells receiving control antibod-
ies (purified nonimmune IgG, Zymed) initiated DNA repli-
cation during a subsequent 18 hr incubation time (Fig. 5D) at
a frequency indistinguishable from that observed in uninjected
cells (80–90%). A quantitative summary of the microinjection
data is shown in Fig. 6.
DISCUSSION
Three major conclusions are supported by this work. First,
expression of mammalian Cdc6 is limited to proliferating cells.
This is true for human diploid fibroblasts and human T24
epithelial cells propagated in culture, and for mucosal cells of
the mouse duodenum growing within the intact animal. Sec-
ond, transcription of mammalian Cdc6 genes is regulated by
E2F transcription factors. This conclusion is based on trans-
activation of the endogenous human Cdc6 gene by forced
expression of E2F:DP1 heterodimers, and on the requirement
for intact E2F recognition motifs for physiological regulation
(repression) of a transfected human Cdc6 promoter under
conditions of growth arrest in murine 3T3 cells. Third, Cdc6 is
required for DNA replication in mammalian cells. The time
course of Cdc6 expression in advance of the G1yS transition in
human cells released from contact inhibition is consistent with
a role for Cdc6 in establishing prereplication complexes, and
immunodepletion of Cdc6 prevents initiation of DNA repli-
cation in HeLa cells.
The manner in which the activity of E2F transcription
factors is modulated by interactions with members of the
retinoblastoma protein (pRb) family, under the control of
cyclin dependent protein kinases, has been characterized
extensively in mammalian cells. Inherited or acquired genetic
abnormalities that perturb this pathway are a common feature
FIG. 4. (A) Quiescent, serum-deprived human foreskin fibroblasts
(passage 7) were infected with the indicated recombinant adenoviruses,
each at an multiplicity of infection of 300, and then harvested for
Northern blot analysis at 15 hr postinfection. Blots were hybridized with
a human Cdc6 probe, or with a glyceraldehyde-3-phosphate dehydroge-
nase probe as a control for RNA loading. The samples labeled as E2F1,
E2F2, or E2F3 represent infections with the indicated E2F viruses
together with an adenovirus expressing DP1 to provide the dimeric
partner for E2F. (B) E2F binding sites are required for correct regulation
of the human Cdc6 promoter. Transient transfection assays were per-
formed in subconfluent 3T3 cells under conditions of growth arrest
induced by serum deprivation (t 5 0 hr), and at subsequent time points
after readdition of serum. Reporter gene activity (mean of triplicate
determinations) was calculated relative to expression of a cytomegalovi-
rus-luciferase gene in sister cultures assayed at each time interval, and
displayed in relation to endogenous Cdc6 mRNA (Northern blot analysis;
calculated as multiples of the hybridization signal at t 5 0 hr) and to the
fraction of cells in S phase (flow cytometry). Similar results were obtained
in each of four separate transfection assays. A schematic representation
of the human Cdc6 promoter illustrates E2F binding sites in relation to
the transcriptional start site (arrow) of the human Cdc6 gene (14), and
disruption of these sites (X) in the mutated promoter.
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of human malignancies (22, 26), and viral oncoproteins trans-
form human cells, at least in part, through interactions that
lead to deregulation of E2F activity (27).
By comparison, the protein–protein and protein–DNA in-
teractions that function directly to specify and control origins
of DNA replication in human cells are poorly defined, and
current mechanistic understanding of replication initiation is
based almost entirely on results from yeast models (1). The
recent identification of human ORC (28) and Cdc6 (14)
proteins provides new opportunities to advance knowledge in
this area. Previous work has shown that overexpression of E2F
proteins can lead to an induction of S phase in otherwise
growth-arrested cells (29–32), indicating that downstream
targets of E2F are capable of promoting initiation of DNA
replication. While our current results do not define molecular
details of the mechanisms by which Cdc6 transcription is
regulated by E2Fs, our data are consistent with the previous
observation that human ORC1 transcription is controlled by
E2F (25) and link the pRb-E2F pathway to the control of
replication origins in human cells. What remains to be deter-
mined is the extent to which E2F imparts only negative control
of the Cdc6 gene or whether E2F also contributes directly to
positive control as cells reenter the cell cycle. For instance, it
is possible that overexpression of E2F activity in quiescent cells
inactives or displaces an endogenous E2F repressor complex,
thus leading to activation of the gene. Further experiments will
be necessary to ascertain whether direct activation of Cdc6
transcription by E2F complexes also contributes to physiolog-
ical regulation of DNA replication.
Cdc6 gene expression in rapidly proliferating S. cerevisiae is
under transcriptional control during late G2, and yeast Cdc6 is
expressed most abundantly in the period between late M phase
and early S phase (6, 33). Under conditions in which G1 is
FIG. 5. Immunodepletion of Cdc6 blocks DNA replication in HeLa cells. Metaphase cells were microinjected with affinity purified anti-Cdc6
(A–C) or control non-immune IgG (D), each at a concentration of 1.5 mgyml, and cultured subsequently for 18 hr in the presence of
bromodeoxyuridine (BrdUrd). Microinjected antibodies (green) and nuclear incorporation of BrdUrd (red) were detected by immunofluoresence
microscopy. The nuclei of microinjected cells that incorporate BrdUrd appear yellow in the double immunofluorescence images.
FIG. 6. Quantitative analysis of BrdUrd incorporation in unin-
jected cells and in cells microinjected with the indicated antibodies.
The number of cells scored for DNA replication in each test condition
is indicated.
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prolonged, a second peak of yeast Cdc6 gene transcription in
late G1 is driven by factors that are functionally analogous to
mammalian E2F proteins with respect to control by cyclin-
dependent kinases and mitogenic signaling pathways (3, 7).
Other mechanisms that govern the abundance of Cdc6 in yeast,
however, may differ from those responsible for its regulation
in mammalian cells. Yeast Cdc6 is an unstable protein, and
degradation of Cdc6 following S phase contributes to its
prominent cyclic variation across the yeast cell cycle (6). Our
current analysis of Cdc6 expression in asynchronously or
synchronously replicating human T24 cells, like our previous
studies of HeLa cells separated by centrifugal elutriation (14),
did not reveal evidence for a major decline in the abundance
of Cdc6 following S phase in cycling cells, but additional
experiments are required to provide a definitive understanding
of the cell cycle dependent regulation of Cdc6 in human cells,
as opposed to the growth regulated control examined in these
current studies.
In general, the data presented here support the view that
fundamental molecular mechanisms controlling initiation of
DNA replication are conserved in all eukaryotes. We cannot
yet ascertain the extent to which human Cdc6 manifests the full
repertoire of distinctive and interesting properties of its yeast
homologs. The finding that Cdc6 is required for initiation of
DNA replication in human cells suggests, however, that de-
regulated expression of Cdc6 may play a role in oncogenic
transformation or disease progression in human cancers, and
that Cdc6 provides a good target for biotechnological strate-
gies designed to arrest cell proliferation.
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